SA PRO
Free Account
Jasper Therapeutics, Inc.JSPRNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 73% recommend buying.

Consensus Rating
Buy
11 analysts·Moderate coverage
73%
Rating Distribution
Strong Buy
00%
Buy
873%
Hold
327%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 9, 2025RBC Capital
Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital
Target:$48.00
+171.0%from $17.71
Dec 5, 2024BMO Capital
BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform
Target:$63.00
+192.6%from $21.53
May 6, 2024H.C. Wainwright
H.C. Wainwright Starts Jasper Therapeutics (JSPR) at Buy, "an underappreciated gem in the autoimmune and inflammatory disease space"
Target:$65.00
+165.1%from $24.52
Apr 3, 2024Evercore ISI
Evercore ISI Starts Jasper Therapeutics (JSPR) at Outperform
Target:$65.00
+148.1%from $26.20
Feb 7, 2023Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Lowers Price Target to $6
Target:$6.00
+212.5%from $1.92
Jan 11, 2023Credit Suisse
Credit Suisse Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $3
Target:$3.00
+81.8%from $1.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance